Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2116522 | Cancer Letters | 2009 | 8 Pages |
Abstract
We have examined whether and by what mechanism piceatannol inhibits cell cycle progression in DU145 cells. The treatment of cells with piceatannol for 24 h resulted in an increase in the percentage of cells in G1 phase and dose-dependent decreases in [3H]thymidine incorporation, as well as in protein levels of cyclin A, cyclin D1, and cyclin-dependent kinase (CDK)2 and CDK4. Piceatannol exerted no effect on the levels of p21WAF1/CIP1 or p27KIP1. Piceatannol reduced CDK4 and CDK2 activity. These results indicate that delaying G1 cell cycle progression contributes to the piceatannol-mediated inhibition of DU145 cell growth, which may be mediated via the inhibition of CDK activity.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Yeo Myeong Lee, Do Young Lim, Han Jin Cho, Mi Ra Seon, Jin-Kyung Kim, Boo-Yong Lee, Jung Han Yoon Park,